Glenda Gray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9406992/publications.pdf

Version: 2024-02-01

236925 182427 6,258 52 25 51 citations h-index g-index papers 60 60 60 9063 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine, 2021, 384, 2187-2201.	27.0	1,954
2	Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet, The, 2004, 363, 1415-1421.	13.7	1,041
3	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. New England Journal of Medicine, 2022, 386, 494-496.	27.0	570
4	A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Motherâ€toâ€Child Transmission of Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 2003, 187, 725-735.	4.0	328
5	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 2021, 384, 1003-1014.	27.0	270
6	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
7	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults. New England Journal of Medicine, 2021, 384, 1089-1100.	27.0	144
8	Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. Infection and Immunity, 2018, 86, .	2.2	136
9	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. New England Journal of Medicine, 2022, 386, 847-860.	27.0	132
10	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host and Microbe, 2021, 29, 1611-1619.e5.	11.0	106
11	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV,the, 2018, 5, e366-e378.	4.7	86
12	A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. Aids, 2005, 19, 1289-1297.	2.2	82
13	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	4.7	81
14	High Asymptomatic Carriage With the Omicron Variant in South Africa. Clinical Infectious Diseases, 2022, 75, e289-e292.	5.8	74
15	Approaches to preventative and therapeutic HIV vaccines. Current Opinion in Virology, 2016, 17, 104-109.	5.4	72
16	Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. New England Journal of Medicine, 2022, 386, 2243-2245.	27.0	65
17	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
18	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet, The, 2022, 399, 1141-1153.	13.7	51

#	Article	IF	CITATIONS
19	Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. International Journal of STD and AIDS, 2018, 29, 531-539.	1.1	48
20	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Science Translational Medicine, 2019, 11 , .	12.4	46
21	Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. New England Journal of Medicine, 2021, 385, 570-571.	27.0	42
22	Cross-sectional study of female sex workers in Soweto, South Africa: Factors associated with HIV infection. PLoS ONE, 2017, 12, e0184775.	2.5	38
23	Depression and Post Traumatic Stress amongst female sex workers in Soweto, South Africa: A cross sectional, respondent driven sample. PLoS ONE, 2018, 13, e0196759.	2.5	32
24	Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis. PLoS Pathogens, 2020, 16, e1008559.	4.7	31
25	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2022, 75, e857-e864.	5.8	30
26	Estimating the contribution of key populations towards HIV transmission in South Africa. Journal of the International AIDS Society, 2021, 24, e25650.	3.0	28
27	Exposure to and experiences of violence among adolescents in lower socio-economic groups in Johannesburg, South Africa. BMC Public Health, 2015, 15, 450.	2.9	27
28	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: AÂrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Medicine, 2020, 17, e1003038.	8.4	27
29	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Vaccine Journal, 2016, 23, 496-506.	3.1	24
30	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Statistical Communications in Infectious Diseases, $2011, 3, .$	0.2	23
31	HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS ONE, 2017, 12, e0188606.	2.5	20
32	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens, 2021, 17, e1009363.	4.7	19
33	Review of preventative HIV vaccine clinical trials in South Africa. Archives of Virology, 2020, 165, 2439-2452.	2.1	18
34	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Scientific Reports, 2020, 10, 2093.	3.3	17
35	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. PLoS Biology, 2016, 14, e1002372.	5.6	12
36	Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	4.0	11

#	Article	IF	CITATIONS
37	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports, 2020, 10, 13031.	3.3	10
38	Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Medicine, 2022, 19, e1004024.	8.4	10
39	Community-led cross-sectional study of social and employment circumstances, HIV and associated factors amongst female sex workers in South Africa: study protocol. Global Health Action, 2021, 14, 1953243.	1.9	9
40	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. PLoS ONE, 2014, 9, e103446.	2.5	9
41	Implementation of a PMTCT programme in a high HIV prevalence setting in Johannesburg, South Africa: 2002–2015. Southern African Journal of HIV Medicine, 2020, 21, 1024.	0.9	9
42	The HIV Cascade of Care and Service Utilisation at Sex Work Programmes Among Female Sex Workers in South Africa. AIDS and Behavior, 2022, 26, 2907-2919.	2.7	8
43	Recreational ART use among individuals living with HIV/AIDS in South Africa: Examining longitudinal ART initiation and viral suppression. Drug and Alcohol Dependence, 2019, 198, 192-198.	3.2	7
44	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	6.0	7
45	Sexual IPV and non-partner rape of female sex workers: Findings of a cross-sectional community-centric national study in South Africa. SSM Mental Health, 2021, 1, 100012.	1.8	7
46	Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. Journal of Infectious Diseases, 2022, 226, 979-982.	4.0	7
47	HIV research in South Africa: Advancing life. South African Medical Journal, 2019, 109, 36.	0.6	6
48	The path to find an HIV vaccine. Journal of the International AIDS Society, 2021, 24, e25749.	3.0	6
49	Sex work and young women: a cross sectional study to understand the overlap of age and sex work as a central tenet to epidemic control in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 555-563.	1.2	5
50	Allergic reactions to the Ad26.COV2.S vaccine in South Africa. , 2022, 1, 2-8.		3
51	An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition. Frontiers in Immunology, 2021, 12, 760571.	4.8	2
52	Randomised trials of COVID-19 vaccines in Africa – charting the path forward. South African Journal of Science, 2022, 118, .	0.7	1